Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

58 citing papers in PubMed.

1. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.JAMA · 2021
   Trial
2. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.Bone marrow transplantation · 2017
   Trial
3. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.Bone marrow transplantation · 2016
   Trial
4. Blinatumomab Redirects Donor Lymphocytes against CD19International journal of molecular sciences · 2023
   Article
5. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.Cancers · 2023
   Review
6. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.Therapeutic advances in hematology · 2023
   Review
7. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.Cancers · 2022
   Review
8. Development of CAR T Cell Therapy in Children-A Comprehensive Overview.Journal of clinical medicine · 2022
   Review
9. Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond.Frontiers in pediatrics · 2022
   Review
10. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).Journal of clinical medicine · 2021
    Review
11. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
12. Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?Frontiers in pediatrics · 2021
    Review
13. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.Clinical case reports · 2020
    Article
14. Immunotherapies for pediatric cancer: current landscape and future perspectives.Cancer metastasis reviews · 2019
    Review
15. Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.Journal of clinical medicine · 2019
    Review
16. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?Current oncology reports · 2019
    Review
17. Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.Bone marrow transplantation · 2019
    Review
18. Prevention and treatment of relapse after stem cell transplantation with immunotherapy.Bone marrow transplantation · 2018
    Review
19. Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.Gene therapy · 2017
    Article
20. Acute myeloid leukemia targets for bispecific antibodies.Blood cancer journal · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as